Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Dec 26;15(1):136.
doi: 10.3390/cancers15010136.

Time for Dynamic Assessment of Fitness in Acute Myeloid Leukemia

Raffaele Palmieri  1   2 , Luca Maurillo  1 , Maria Ilaria Del Principe  1 , Giovangiacinto Paterno  1 , Roland Bruno Walter  2   3   4   5 , Adriano Venditti  1 , Francesco Buccisano  1
Affiliations
Editorial

Time for Dynamic Assessment of Fitness in Acute Myeloid Leukemia

Raffaele Palmieri et al. Cancers (Basel). .

Abstract

Informed treatment decision-making in acute myeloid leukemia (AML) requires a comprehensive evaluation of all clinical and biological features that may affect the outcome with any given type or intensity of therapy [...].

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Critical time points for Clinical and Biological Fitness assessment.
See this image and copyright information in PMC

References

    1. Palmieri R., Paterno G., De Bellis E., Mercante L., Buzzatti E., Esposito F., Del Principe M.I., Maurillo L., Buccisano F., Venditti A. Therapeutic Choice in Older Patients with Acute Myeloid Leukemia: A Matter of Fitness. Cancers. 2020;12:120. doi: 10.3390/cancers12010120. - DOI - PMC - PubMed
    1. Döhner H., Wei A.H., Appelbaum F.R., Craddock C., DiNardo C.D., Dombret H., Ebert B.L., Fenaux P., Levine R.L., Löwenberg B., et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood J. Am. Soc. Hematol. 2022;140:1345–1377. doi: 10.1182/blood.2022016867. - DOI - PubMed
    1. Ferrara F., Barosi G., Venditti A., Angelucci E., Gobbi M., Pane F., Tosi P., Zinzani P., Tura S. Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: A project of SIE, SIES and GITMO group on a new tool for therapy decision making. Leukemia. 2013;27:997–999. doi: 10.1038/leu.2012.303. - DOI - PubMed
    1. Walter R.B., Othus M., Borthakur G., Ravandi F., Cortes J., Pierce S.A., Appelbaum F.R., Kantarjian H.A., Estey E.H. Prediction of Early Death After Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia With Pretreatment Risk Scores: A Novel Paradigm for Treatment Assignment. J. Clin. Oncol. 2011;29:4417–4424. doi: 10.1200/JCO.2011.35.7525. - DOI - PMC - PubMed
    1. Sorror M.L., Storer B.E., Fathi A.T., Brunner A.M., Gerds A.T., Sekeres M.A., Mukherjee S., Medeiros B.C., Wang E.S., Vachhani P., et al. Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia. Blood. 2021;138:387–400. doi: 10.1182/blood.2020008812. - DOI - PMC - PubMed

Publication types

LinkOut - more resources